NZ324314A - Process for the diagnosis and treatment of squamous cell carcinomas based on the expression of the variable exon v6 of the CD44 gene - Google Patents

Process for the diagnosis and treatment of squamous cell carcinomas based on the expression of the variable exon v6 of the CD44 gene

Info

Publication number
NZ324314A
NZ324314A NZ324314A NZ32431496A NZ324314A NZ 324314 A NZ324314 A NZ 324314A NZ 324314 A NZ324314 A NZ 324314A NZ 32431496 A NZ32431496 A NZ 32431496A NZ 324314 A NZ324314 A NZ 324314A
Authority
NZ
New Zealand
Prior art keywords
antibody
lymph node
node metastasis
larynx
expression
Prior art date
Application number
NZ324314A
Other languages
English (en)
Inventor
Karl-Heinz Heider
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Karlsruhe Forschzent
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Karlsruhe Forschzent, Boehringer Ingelheim Int filed Critical Karlsruhe Forschzent
Publication of NZ324314A publication Critical patent/NZ324314A/en

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ324314A 1995-12-06 1996-12-05 Process for the diagnosis and treatment of squamous cell carcinomas based on the expression of the variable exon v6 of the CD44 gene NZ324314A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (1)

Publication Number Publication Date
NZ324314A true NZ324314A (en) 2000-02-28

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ324314A NZ324314A (en) 1995-12-06 1996-12-05 Process for the diagnosis and treatment of squamous cell carcinomas based on the expression of the variable exon v6 of the CD44 gene

Country Status (25)

Country Link
EP (1) EP0865609B1 (enExample)
JP (1) JP2000502067A (enExample)
KR (1) KR100473824B1 (enExample)
CN (1) CN1151377C (enExample)
AR (1) AR004360A1 (enExample)
AT (1) ATE235056T1 (enExample)
AU (1) AU726704B2 (enExample)
BG (1) BG62985B1 (enExample)
BR (1) BR9611901A (enExample)
CA (1) CA2239709A1 (enExample)
CO (1) CO4520233A1 (enExample)
CZ (1) CZ174198A3 (enExample)
DE (1) DE59610248D1 (enExample)
DK (1) DK0865609T3 (enExample)
EE (1) EE03783B1 (enExample)
ES (1) ES2190484T3 (enExample)
MX (1) MX9804459A (enExample)
NO (1) NO319903B1 (enExample)
NZ (1) NZ324314A (enExample)
PL (1) PL184521B1 (enExample)
PT (1) PT865609E (enExample)
SK (1) SK284378B6 (enExample)
TR (1) TR199801027T2 (enExample)
UY (1) UY24389A1 (enExample)
WO (1) WO1997021104A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP5763105B2 (ja) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODY AND USES THEREOF
IL317000A (en) 2022-05-25 2025-01-01 Akiram Therapeutics Ab Antibodies against CD44V6 and their use in the treatment of cancers that overexpress CD44V6

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
WO1995000851A1 (de) * 1993-06-22 1995-01-05 Boehringer Ingelheim International Gmbh Verfahren zur diagnose und analyse von tumoren
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
NO319903B1 (no) 2005-09-26
KR19990071952A (ko) 1999-09-27
MX9804459A (es) 1998-09-30
JP2000502067A (ja) 2000-02-22
EE03783B1 (et) 2002-06-17
CZ174198A3 (cs) 1999-02-17
EE9800164A (et) 1998-12-15
DE59610248D1 (de) 2003-04-24
UY24389A1 (es) 2001-10-25
AR004360A1 (es) 1998-11-04
BR9611901A (pt) 1999-03-02
CA2239709A1 (en) 1997-06-12
KR100473824B1 (ko) 2005-09-30
SK284378B6 (sk) 2005-02-04
NO982588D0 (no) 1998-06-05
PL327066A1 (en) 1998-11-23
ATE235056T1 (de) 2003-04-15
CN1151377C (zh) 2004-05-26
HK1011560A1 (en) 1999-07-16
EP0865609A1 (de) 1998-09-23
DK0865609T3 (da) 2003-06-23
AU1177397A (en) 1997-06-27
BG62985B1 (bg) 2000-12-29
AU726704B2 (en) 2000-11-16
PT865609E (pt) 2003-08-29
NO982588L (no) 1998-08-05
ES2190484T3 (es) 2003-08-01
CN1207811A (zh) 1999-02-10
SK73698A3 (en) 1999-01-11
BG102513A (en) 1999-02-26
TR199801027T2 (xx) 1998-10-21
WO1997021104A1 (de) 1997-06-12
CO4520233A1 (es) 1997-10-15
PL184521B1 (pl) 2002-11-29
EP0865609B1 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
US5916561A (en) Monoclonal antibody against CD44v6
US8273550B2 (en) Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
EP1766017A1 (en) Tumor specific antibody
AU726704B2 (en) Method of diagnosing and treating epithelioma
US6372441B1 (en) Method for diagnosis and therapy of Hodgkin's lymphomas
CA2168988A1 (en) Polypeptides coded by exon v5 of the cd44 gene as targets for immunotherapy and immunoscintigraphy of tumours
RU2193779C2 (ru) Средство и способ лечения плоскоклеточного рака
MXPA96006108A (es) Anticuerpos monoclonales contra cd44v6
HK1011560B (en) Method of diagnosing and treating epithelioma
MXPA99005544A (es) Molecula de anticuerpo y su empleo para la diagnosis y terapia de linfomas de hodgkin
HK1114124A (en) Cancer specific antibody and cell surface proteins

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)